Introduction
============

*Klebsiella* spp. are Gram-negative rods that can lead to a wide range of disease states, most notably chest and urinary tract infections, septicemia, meningitis, diarrhea, and soft tissue infections. Major chest infections due to *Klebsiella* spp. include pneumonia, lung abscess, and empyema. *Klebsiella* spp. infection is an independent prognostic factor in pneumonia ([@B1],[@B2]), the mortality of which was reported to be 41% (7 of 15 patients) within 14 days after diagnosis ([@B3],[@B4]).

In Japan, the aging demographic structure is becoming pronounced, and the full-blown graying of society appears to be not far off, which indicates an increasing population that will require healthcare contact. *Klebsiella* spp. are major pathogens in healthcare-associated infections, and their importance appears to be increasing ([@B5]). One clinical report from an Asian tertiary teaching hospital showed that *Klebsiella* spp. and *Streptococcus pneumoniae* are two leading pathogens of healthcare-associated pneumonia ([@B6]). It has been reported that patients with *K. pneumoniae* chest infection frequently suffer a rapid, fatal outcome ([@B7]), and physicians should understand the clinical characteristics of *Klebsiella* chest infections; however, there have been no recent reports investigating how chest infections due to *Klebsiella* spp. differ from those due to other pathogens.

We therefore investigated the characteristics of *Klebsiella* chest infections by comparing the differences in clinical and radiologic features of chest infections due to *Klebsiella* spp. with those due to *S. pneumoniae*, which is a major pathogen of chest infections.

Materials and Methods
=====================

We conducted a retrospective study of consecutive patients hospitalized with pneumonia \[community-acquired pneumonia (CAP) or healthcare-associated pneumonia (HCAP)\], lung abscess/necrotizing pneumonia, and empyema due to *Klebsiella* spp. and *S. pneumoniae* from January 2002 through November 2017 at our institution in Saitama, Japan.

Lung abscess/necrotizing pneumonia was diagnosed when chest computed tomography (CT) showed cavitary lesions in areas of pulmonary consolidation. Empyema was diagnosed when the pleural effusion was pus or when it met the criteria of class 4 to 7 pleural effusion ([@B8]). Parapneumonic effusion was diagnosed when pleural effusion did not meet the above criteria of empyema or could not be evaluated because of its small amount.

Smoking status was classified into current smoker (someone who has smoked greater than 100 cigarettes in their lifetime and has smoked in the last 28 days), ex-smoker (someone who has smoked greater than 100 cigarettes in their lifetime but has not smoked in the last 28 days), and never-smoker (someone who has not smoked greater than 100 cigarettes in their lifetime and does not currently smoke). Alcohol habit (drinking level) was classified into 3 levels: heavy drinking (consumption of 8 or more drinks per week for women and 15 or more drinks per week for men) ([@B9]), moderate drinking (up to 1 drink per day for women and up to 2 drinks per day for men), and slight drinking (fewer than the moderate level) or non-drinking. The performance status (PS) ([@B10]) of the patients for performing daily life activities before the development of chest infections was recorded on admission based on anamnesis from the patients and their families. Excluded patients comprised those with tuberculosis or a confirmed alternative diagnosis lasting until the end of the follow-up period.

Diagnosis of causative microorganisms was based on the results from the semiquantitative culture of respiratory samples or blood, paired sera, urinary antigen tests for *S. pneumoniae* and *Legionella pneumophila*, and nasopharyngeal rapid diagnostic test and reverse transcription polymerase chain reaction for influenza virus, as reported previously ([@B11],[@B12]). Biochemical bacterial identification of the isolated bacteria from patients was performed with an automated bacterial identification system (Vitek 2 GN; Sysmex bioMérieux, Tokyo, Japan). Broth microdilution was carried out according to the Clinical and Laboratory Standards Institute (CLSI) guidelines for antibiotics ([@B13]). The production of extended-spectrum beta-lactamase (ESBL) was screened and confirmed in accordance with the standards of the CLSI ([@B12]). HCAP was defined according to the criteria of the American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) guidelines ([@B4]). Severe disease was defined when at least 1 major criterion (invasive mechanical ventilation, septic shock with the need for vasopressors) or 3 minor criteria (respiratory rate ≥30 breaths/min, partial pressure of arterial oxygen (PaO~2~)/fraction of inspiratory oxygen (FiO~2~) ratio ≤250, multilobar infiltrates, confusion/disorientation, uremia, leukopenia, thrombocytopenia, hypothermia, hypotension requiring aggressive fluid resuscitation) of the IDSA/ATS guidelines ([@B14]) were present.

Approval for this study was obtained from the institutional clinical research ethics board of Saitama Cardiovascular and Respiratory Center.

Statistical analyses
--------------------

The results are presented as numbers and percentages, median (range) or means ± standard deviation unless otherwise indicated. Fisher\'s exact test and Student\'s *t*-test were used for categorical and continuous data, respectively. In all instances, a 2-tailed p value of \<0.05 was considered to indicate statistical significance. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, USA).

Results
=======

Patients
--------

From January 2002 to December 2017, 76 patients with *Klebsiella* spp. (K group) and 446 patients with pneumococcal (S group) chest infections were admitted to our institution. All patients were ≥18 years old. There were no HIV-positive patients, patients with non-resected lung cancer, or those undergoing chemotherapeutic treatment. Three patients had mixed infection of both *S. pneumoniae* and *Klebsiella* spp. and were excluded.

Clinical features of each group are listed in [Table 1](#t001){ref-type="table"}. The K group was older and had more males and patients with an impaired premorbid PS than the S group. Alcohol habit in the K group included heavy drinking in 10, moderate drinking in 18, and slight/no drinking in 46 patients. The frequencies of heavy drinking and moderate drinking were greater in the K group than in the S group. Diabetes mellitus and a history of upper digestive system surgery were more frequent in the K group than in the S group.

###### 

Patient Characteristics, Laboratory Data, and Outcomes.

  Characteristic                                                 *Klebsiella* spp. infection (n=76)      Pneumococcal infection (n=446)      p value
  ----------------------------------------------------------- -- ------------------------------------ -- -------------------------------- -- ----------
  Infection type                                                                                                                             
  Pneumonia                                                      45 (59.2%)                              436 (97.8%)                         \<0.0001
  Lung abscess/necrotizing pneumonia                             24 (31.6%)                              4 (0.9%)                            \<0.0001
  Pneumonia plus empyema                                         2 (2.6%)                                2 (0.4%)                            0.1032
  Lung abscess/necrotizing pneumonia plus empyema                2 (2.6%)                                1 (0.2%)                            0.0569
  Empyema                                                        3 (3.9%)                                3 (0.7%)                            0.0428
  Sex, male                                                      66 (86.8%)                              308 (69.1%)                         0.0014
  Age, mean years (standard deviation)                           72.3 (10.95)                            68.8 (13.90)                        0.0337
  Vaccine history, yes                                                                                                                       
  PPV                                                            2 (2.6%)                                20 (4.5%)                           0.7561
  Influenza                                                      3 (3.9%)                                29 (6.5%)                           0.6035
  Smoking status, current smokers                                61 (80.3%)                              283 (63.5%)                         0.0039
  Alcohol habit, Heavy drinking/Usual/Slight or no drinking      10/18/5                                 8/27/411                            \<0.0001
  LTOT                                                           5 (6.6%)                                35 (7.8%)                           0.8192
  Premorbid PS, 0/1-2/3-4                                        27/25/11                                240/114/34                          0.0158
  Type of pneumonia, CAP                                         47 (61.8%)                              303 (67.9%)                         0.2943
  Underlying diseases, yes                                                                                                                   
  COPD                                                           15 (19.7%)                              106 (23.8%)                         0.5563
  Bronchiectasis                                                 6 (7.9%)                                20 (4.5%)                           0.2475
  Pulmonary non-tuberculous mycobacteria                         7 (9.2%)                                19 (4.3%)                           0.0831
  Old tuberculosis                                               4 (5.3%)                                22 (4.9%)                           0.7814
  Chronic pulmonary aspergillosis                                0 (0.0%)                                7 (1.6%)                            0.6009
  Interstitial pneumonia                                         3 (3.9%)                                31 (7.0%)                           0.4528
  History of lung cancer surgery                                 3 (3.9%)                                11 (2.5%)                           0.4407
  Pneumoconiosis                                                 0 (0.0%)                                7 (1.6%)                            0.6009
  Other pulmonary diseases                                       3 (3.9%)                                4 (0.9%)                            0.0671
  Hypertension                                                   11 (14.5%)                              45 (10.1%)                          0.3138
  Congestive heart failure                                       4 (5.3%)                                26 (5.8%)                           1.0000
  Ischemic heart disease                                         1 (1.3%)                                21 (4.7%)                           0.2279
  Diabetes mellitus                                              20 (26.3%)                              47 (10.5%)                          0.0006
  Cerebral vascular disease                                      4 (5.3%)                                32 (7.2%)                           0.8058
  Dementia                                                       2 (2.6%)                                4 (0.9%)                            0.2126
  Neuromuscular disease                                          4 (5.3%)                                5 (1.1%)                            0.0295
  History of upper digestive system surgery                      7 (9.2%)                                14 (3.1%)                           0.0222
  Chronic liver disease                                          2 (2.6%)                                12 (2.7%)                           1.0000
  Connective tissue diseases                                     4 (5.3%)                                14 (3.1%)                           0.3150
  Steroid or immunosuppressant                                   3 (3.9%)                                27 (6.1%)                           0.6006
  Malignant disease                                              1 (1.3%)                                13 (2.9%)                           0.7041
  CKD                                                            2 (2.6%)                                8 (1.8%)                            0.6448
  None                                                           9 (11.8%)                               94 (21.1%)                          0.0628
  Blood tests, median (range) \[number measured\]                                                                                            
  WBC (/mm^3^)                                                   10,600.0 (1,300-240) \[76\]             11,300.0 (600-47,100) \[446\]       0.1170
  Platelets (×10^4^/mm^3^)                                       26.9 (0.8-64.8) \[62\]                  22.9 (4.8-86.8) \[117\]             0.0068
  AST (IU/L)                                                     24.0 (7-514) \[75\]                     25.0 (9-431) \[442\]                0.3553
  LDH (IU/L)                                                     208.0 (41-978) \[76\]                   218.0 (17-923) \[437\]              0.8215
  CK (IU/L)                                                      76.5 (13-1,384) \[58\]                  73.0 (7-20,485) \[400\]             0.4981
  BUN (mg/dL)                                                    16.0 (7-123) \[65\]                     18.0 (5-98) \[437\]                 0.5943
  Creatinine (mg/dL)                                             0.7 (0.3-2.4) \[65\]                    0.7 (0.3-3.4) \[440\]               0.9052
  Na (mmol/L)                                                    138.0 (127-153) \[60\]                  137.0 (116-148) \[143\]             0.1019
  CRP (mg/dL)                                                    13.3 (0.8-54.6) \[65\]                  13.5 (0.09-54.3) \[445\]            0.6862
  Duration, days, mean±standard deviation                                                                                                    
  Antibiotic administration                                      13.3±6.2                                9.5±4.6                             \<.0001
  Hospital stay                                                  22.6±19.7                               17.0±19.2                           0.0179
  Hospital mortality                                             5 (6.6%)                                22 (4.9%)                           0.5731

PPV: pneumococcal polysaccharide vaccine, LTOT: long-term oxygen therapy, PS: performance status, CAP: community-acquired pneumonia, COPD: chronic obstructive pulmonary disease, CKD: chronic kidney disease, WBC: white blood cell count (/mm^3^), AST: aspartate transaminase, LDH: lactate dehydrogenase, CK: creatine kinase, BUN: blood urea nitrogen, CRP: C-reactive protein

Types of chest infections
-------------------------

Pulmonary infection was found in 73 (pneumonia in 45 and lung abscess in 28) of the 76 patients in the K group and in 443 (pneumonia in 438 and lung abscess in 5) of the 446 patients in the S group ([Table 1](#t001){ref-type="table"}). Empyema was found in 5 of the 76 patients in the K group and in 6 of the 446 patients in the S group. Two of the 5 patients with empyema in the K group were complicated with pulmonary infection, and 3 did not show any pulmonary shadows. Compared with the S group, the K group had a higher frequency of patients with a lung abscess or necrotizing pneumonia alone (31.6% vs. 0.9%) and empyema alone (3.9% vs. 0.7%) but a lower frequency of patients with pneumonia alone (59.2% vs. 99.1%).

Klebsiella subspecies
---------------------

The *Klebsiella* subspecies identified included *K. pneumoniae* (n=72), *K. rhinoscleromatis* (n=1), *K. oxytoca* (n=1), and *K. ozaenae* (n=2).

Etiology of mixed infection
---------------------------

Diagnostic methods used to identify etiologies in both the K and S groups are shown in [Table 2](#t002){ref-type="table"}. Mixed infection was found on admission in 19 patients (25.0%). The most common microorganism causing mixed infection in the K group was *Pseudomonas aeruginosa* (n=6), followed by influenza virus (n=4) and other microorganisms ([Table 3](#t003){ref-type="table"}). Patients in the K group were more frequently coinfected by *P. aeruginosa* than those in the S group (7.9% vs. 0.4%, p=0.0002).

###### 

Diagnostic Methods and Results of the Patients in the Present Study (n=522).

  Method                               No. of samples studied      No. of positive diagnostic studies (%)                     
  --------------------------------- -- ------------------------ -- ---------------------------------------- -- ----------- -- ------------
  Paired sera                          343                         36 (10.5)                                   4 (10.8)       32 (10.5)
  Rapid influenza diagnostic test      497                         41 (8.2)                                    4 (7.1)        36 (8.3)
  Urinary antigen                      484                         394 (81.4)                                  1 (2.0)        386 (90.4)
  Culture                                                                                                                     
  Sputum                               477                         215 (45.0)                                  53 (89.8)      157 (39.3)
  Transbronchial aspirate              23                          9 (39.1)                                    6 (60.0)       3 (25.0)
  Protected specimen brush             15                          13 (86.7)                                   12 (100)       1 (33.3)
  Bronchial washing                    18                          12 (66.7)                                   7 (77.8)       5 (62.5)
  Bronchoalveolar lavage fluid         7                           3 (42.9)                                    1 (14.3)       2 (33.3)
  Blood                                340                         26 (7.6)                                    4 (9.8)        22 (7.4)
  Pleural fluid                        18                          9 (50.0)                                    4 (66.7)       4 (36.4)

###### 

Etiologies of Mixed Infection.

  Species                                              *Klebsiella* spp. infection      Pneumococcal infection      p value
  ------------------------------------------------- -- ----------------------------- -- ------------------------ -- ---------
  Mixed infection                                      19 (25.0%)                       104 (23.3%)                 0.7704
  *Haemophilus influe nzae*                            1 (1.3%)                         17 (3.8%)                   0.4934
  *Legionella* sp.                                     0 (0.0%)                         6 (1.3%)                    0.5997
  Influenza virus                                      4 (5.3%)                         53 (11.9%)                  0.1101
  *Pseudomonas aerugino sa*                            6 (7.9%)                         2 (0.4%)                    0.0002
  *Moraxella catar rhalis*                             0 (0.0%)                         5 (1.1%)                    1.0000
  Enterobacteriaceae other than *Klebsiella* spp.      1 (1.3%)                         1 (0.2%)                    0.2702
  *Streptococcus* sp. other than pneumococcus          2 (2.6%)                         1 (0.2%)                    0.0569
  *Chlamydophila pneu moniae*                          2 (2.6%)                         16 (3.6%)                   1.0000
  *Chlamydophi la psittaci*                            1 (1.3%)                         1 (0.2%)                    0.2702
  MSSA                                                 1 (1.3%)                         5 (1.1%)                    1.0000
  Others                                               1 (1.3%)                         1 (0.2%)                    0.2702

MSSA: methicillin-sensitive *Staphylococcus aureus*

Laboratory data on admission
----------------------------

Laboratory data on admission are shown in [Table 1](#t001){ref-type="table"}. The platelet count of patients in the K group was significantly higher than that of patients in the S group (median, 26.9×10^4^/mm^3^ vs. 22.9×10^4^/mm^3^, p=0.007). The ratios of blood cultures positive for *Klebsiella* spp. and *S. pneumoniae* were 4 of 41 (9.8%) and 22 of 294 (7.5%), respectively, in the tested patients.

Antibacterial susceptibility of isolated Klebsiella spp.
--------------------------------------------------------

The antibacterial susceptibilities of the isolated *Klebsiella* spp. are listed in [Table 4](#t004){ref-type="table"}. Susceptibility to penicillins was low; however, β-lactamase inhibitors apparently restored the activities of the penicillins. ESBL-producing *Klebsiella* spp. were found in one patient.

###### 

Antibacterial Susceptibility of Isolated *Klebsiella* species.

                Number tested      Susceptible      (%)
  ---------- -- --------------- -- ------------- -- ------
  ABPC          50                 0                0
  AMPC/CVA      16                 14               87.5
  ABPC/SBT      28                 26               92.9
  PIPC          56                 29               51.8
  PIPC/TAZ      9                  7                77.8
  CAZ           57                 56               98.2
  CEZ           56                 56               100
  CMZ           55                 55               100
  CTRX          12                 12               100
  CFPM          28                 28               100
  IPM           56                 56               100
  MEPM          26                 26               100
  GM            58                 58               100
  AMK           58                 57               98.3
  LVFX          26                 26               100
  CPFX          28                 27               96.4
  MINO          57                 54               94.7
  AZT           58                 48               85.8

ABPC: ampicillin, AMPC: amoxicillin, CVA: clavulanic acid, SBT: sulbactam, PIPC: piperacillin, TAZ: tazobactam, CAZ: ceftazidime, CEZ: cefazolin, CMZ: cefmetazole, CTRX: ceftriaxone, CFPM: cefepime, IPM: imipenem, MEPM: meropenem, GM: gentamicin, AMK: amikacin, LVFX: levofloxacin, CPFX: ciprofloxacin, MINO: minocycline, AZT: aztreonam

Severity on admission
---------------------

In the K group, 15 patients (19.7%) were in a severe condition on admission ([Table 1](#t001){ref-type="table"}) (*K. pneumoniae*, n=12, *K. oryzae*, n=2, *K. rhinoscleromatis*, n=1, *K. oxytoca*, n=1), and 7 (12.3%) patients required mechanical ventilation. The disease in one patient diagnosed with lung abscess/necrotizing pneumonia was compatible with pulmonary gangrene clinically ([Figure](#g001){ref-type="fig"}). The frequency of patients with a severe condition did not differ significantly between the K and S groups (19.7% vs. 18.2%, p=0.7494).

![Images from chest X-ray and computed tomography (CT) performed at the local hospital of a 64-year-old man with a history of hypertension showed bilateral consolidation (a-c). On the 10th day after referral to our hospital (7th hospital day at our institution), CT showed bilateral consolidation with a hyperlucent area (d), and consolidation was replaced by cavitary lesions (e).](1349-7235-59-0611-g001){#g001}

Treatment and outcomes
----------------------

Antibiotics were administered to all patients following admission ([Table 5](#t005){ref-type="table"}). When compared with the patients in the S group, those in the K group more frequently received single penicillins, penicillins combined with β-lactamase inhibitors, and single antibiotic therapy as initial (empirical) antibiotics therapy. Piperacillin was administered to 4 patients of the K group who received single penicillins. Susceptibility of the isolated *K. pneumoniae* to piperacillin was good, and the patients recovered. Patients in the K group required antibiotics for a longer duration and showed a longer hospital stay than those in S group ([Table 1](#t001){ref-type="table"}). Five patients in the K group died (*K. pneumonia*, n=4, *K. oryzae*, n=1), but the in-hospital mortality did not differ significantly between the K and S groups.

###### 

Treatment and Outcomes.

                                                                             *Klebsiella* spp. infection (n=76)   Pneumococcal infection (n=446)   p value
  -------------------------------------------------------------------------- ------------------------------------ -------------------------------- ---------
  Mechanical ventilation                                                     7 (9.2%)                             19 (4.3%)                        0.0831
  Initial antibiotics                                                                                                                              
  Carbapenems, 3rd- or 4th-generation cephalosporins plus macrolides         3 (3.9%)                             62 (13.9%)                       0.0135
  Carbapenems, 3rd- or 4th-generation cephalosporins plus fluoroquinolones   1 (1.3%)                             9 (2.0%)                         1.0000
  Carbapenems, 3rd- or 4th-generation cephalosporins plus minocyclines       1 (1.3%)                             2 (0.4%)                         0.3769
  Single carbapenems, 3rd- or 4th-generation cephalosporins                  9 (11.8%)                            41 (9.2%)                        0.5255
  Penicillins plus macrolides                                                0 (0%)                               2 (0.4%)                         1.0000
  Single penicillins                                                         4 (5.3%)                             4 (0.9%)                         0.0184
  Penicillins combined with β-lactamase inhibitors                           27 (35.5%)                           109 (24.4%)                      0.0480
  Penicillins combined with β-lactamase inhibitors plus macrolides           27 (35.5%)                           179 (40.1%)                      0.5258
  Penicillins combined with β-lactamase inhibitors plus fluoroquinolones     1 (1.3%)                             13 (2.9%)                        0.7041
  Penicillins combined with β-lactamase inhibitors plus minocyclines         1 (1.3%)                             3 (0.7%)                         0.4681
  Others                                                                     1 (1.3%)                             5 (1.1%)                         1.0000
  Number of antibiotics for initial treatment                                                                                                      
  Single drug                                                                40 (52.66%)                          171 (38.3%)                      0.0227
  ≥2 drugs                                                                   36 (47.4%)                           275 (61.7%)                      

Discussion
==========

To our knowledge, there have been few reports comparing clinical features between *Klebsiella* and pneumococcal chest infection. Lin et al. compared the characteristics of bacteremic lobar pneumonia due to *Klebsiella* spp. (mean patient age, 73 years old) and *S. pneumoniae* (mean patient age, 76 years old), and patients with bacteremic *Klebsiella* pneumonia showed a lower white blood cell count, higher frequency of bilateral involvement on chest X-ray, greater disease severity on admission, more frequent admission to the intensive-care unit, and higher mortality rate than those with bacteremic pneumococcal pneumonia ([@B15]). In that report, the frequencies of male gender, diabetes mellitus, alcoholism, and cavitary lesions on chest X-ray did not differ markedly between the two groups ([@B15]).

In the present study, there were significant differences in several patient demographics and laboratory data, but no differences were noted in the frequency of patients with severe conditions or mortality between the two groups. Severity and mortality are affected by several factors, including patient demographics and treatment ([@B11],[@B12]). In addition, the prevalence of virulent factors differs across countries and regions ([@B16]). For example, the prevalence of K1 isolates is higher in Japan than in the United States or Europe but lower than in Taiwan ([@B16]). These differences are likely the cause of the difference in results between the previous studies ([@B15],[@B17]) and ours.

Pneumonia caused by *Klebsiella* spp. has been reported to occur predominantly in men in their 60s, in chronic alcoholics ([@B18]), and in patients with conditions such as chronic bronchopulmonary diseases, cardiac diseases, diabetes mellitus, and malignancy ([@B18],[@B19]). Our patients in the K group showed impaired premorbid PS, suggesting that debilitated patients may be predisposed to *Klebsiella* spp. infection ([@B18]). The major underlying conditions in patients with *Klebsiella* spp. infection tend to be chronic diseases that require contact with healthcare providers, and the frequency of *Klebsiella* spp. infection was reported to be lower in patients with CAP than in those with HCAP ([@B18]). An impaired PS is not included in the diagnostic criteria of HCAP but is included in those of nursing- and healthcare-associated pneumonia, which is a Japanese variant of HCAP ([@B20]). The higher proportion of patients with an impaired PS in the K group than in the S group suggests that a higher proportion of patients in the K group likely had nursing- and healthcare-associated pneumonia. These characteristics may be one reason for the longer duration of antibiotics treatment and hospital stay in the K group patients, which is compatible with the findings of a previous report ([@B21]). The higher proportion of lung abscesses, necrosis, and empyema in the K group may also explain the longer duration of antibiotic treatment, as empyema and lung abscesses frequently require longer antibiotics administration than pneumonia ([@B22]).

Although *K. pneumoniae* remains the primary species causing human diseases such as pneumonia, numerous causative *Klebsiella* species have been identified, including *K. pneumoniae* (*K. pneumoniae* subsp. *pneumoniae*), *K. rhinoscleromatis* (*K. pneumoniae* subsp. *rhinoscleromatis*), *K. ozaenae* (*K. pneumoniae* subsp. *ozaenae*), *K. planticola*, and *K. ornithinolytica*. *Klebsiella* spp. can colonize or cause chronic upper and lower respiratory tract infections, septicemia, and severe pneumonia ([@B18]-[@B21],[@B23]-[@B25]), and severe cases of infection were also found in our patients with *K. rhinoscleromatis*, *K. ozaenae*, and *K. oxytoca*.

Polymicrobial infection was found in 19 of our 76 (25.0%) patients in the K group, which was similar to the 27% frequency in a previous report of *Klebsiella* pneumonia ([@B4]). *P. aeruginosa* was the leading pathogen of coinfection with *Klebsiella* species in our study. The K group patients had an impaired PS more frequently than those in the S group, suggesting that the K group patients may have received nursing and home-care service more frequently than those in the S group ([@B20]) with a risk of multidrug-resistant pathogen infection, including *P. aeruginosa* ([@B20]). Previously reported results investigating mixed infection were mainly based on culture results ([@B26]). We evaluated the etiology of mixed infection by paired sera and rapid diagnostic tests. As a result, influenza virus was the second-most frequent pathogen found to be coinfecting with *K. pneumoniae*. Damaged epithelium and an impaired defense mechanism in local and systemic immune systems may induce infections caused by *Klebsiella* species ([@B27]). There have been few reports of pneumonia due to coinfection of influenza and *Klebsiella* species ([@B28]), but the frequency of coinfection with influenza in the K group did not differ markedly from that in the S group. Influenza is a common disease, and such coinfection may be underrecognized. The investigation of polymicrobial infection seems to result in both a better selection of appropriate antibiotics and better infection control, especially in patients with influenza coinfection.

A previous report that investigated chest CT findings of *Klebsiella* pneumonia in 23 cases showed pleural effusion in 8 cases and necrosis or cavities in all cases. Two cases showed clinical courses compatible with pulmonary gangrene ([@B29]). In our study, we defined lung abscess/necrotizing pneumonia when cavities were found in areas of pulmonary consolidation. A cavity is the result of pathological processes, including suppurative necrosis, caseous necrosis, ischemic necrosis, and cystic dilatation of lung structures. *K. pneumoniae* is associated with extensive pyogenic lung necrosis and frequent cavitation, and this organism is also disproportionately represented among cases of pulmonary gangrene, in which there is extensive pulmonary necrosis and infarction. These findings suggest that the organism possesses pathogenic determinants that lead to pulmonary necrosis and cavitation more frequently than *S. pneumoniae* ([@B30],[@B31]). A previous report of 205 patients with lung abscess included 10 cases (4.9%) due to *Klebsiella* spp. but only 3 cases (1.5%) due to *S. pneumoniae* ([@B32]). Another study from Taiwan implicated *K. pneumoniae* as the most common single cause of lung abscess, isolated from 28 of 90 (31%) patients with lung abscesses ([@B33]). These results suggest that the detection of cavity formation suggests a *Klebsiella* spp. infection rather than a *S. pneumoniae* infection.

Our study showed a higher percentage of empyema alone in the K group than in the S group; however, the number of patients with empyema alone was 3 in both groups. Because *S. pneumoniae* is a common cause of chest infection, it may cause a significant fraction of empyema cases, even though pneumococcal pneumonia complicated empyema less frequently than *Klebsiella* pulmonary infection (pneumonia and lung abscess/necrotizing pneumonia). Certainly, the etiology of empyema in a previous study included *Klebsiella* spp. in 23 (3.5%) and *S. pneumonia* in 81 (12.5%) of 650 patients ([@B8]). Thus, we think it difficult to differentiate *Klebsiella* spp. infection and pneumococcal infection based on complication of empyema.

*S. pneumoniae* is generally susceptible to penicillins; however, *K. pneumoniae* is frequently resistant to penicillins because it produces a penicillin-specific β-lactamase ([@B34]), which may result in treatment failure of the initial antibiotics. Results of the antibacterial susceptibility of isolated *Klebsiella* species in our patients were similar to those reported throughout Japan ([@B35]). Our K group patients frequently received single penicillins as initial antibiotics. Fortunately, the single penicillin administered in these patients was piperacillin, to which the isolated *Klebsiella* spp. were susceptible; however, about half of the isolated *Klebsiella* spp. showed resistance to piperacillin, which may cause an unfavorable clinical course in other patients. Correct prediction of *Klebsiella* spp. infection results in better antibiotics selection. Our results indicated that patients\' demographics and radiologic findings (cavity formation) may be clues to differentiate between infections caused by these two pathogens.

There are several limitations in the present study. It is a retrospective, single-center study with a limited number of patients, so the results may not be applicable to other settings. In addition, we did not investigate the presence of certain factors (K1 and K2 antigen), genes (*rmp A* and *mag A*), or phenotypes (hypermucoviscosity) with increased pathogenicity. It may be best to investigate these factors in future studies when assessing the clinical features of *Klebsiella* infections. We adopted the 2007 IDSA/ATS severity criteria for CAP to compare the disease severity between the K and S groups. This score can also be applied to HCAP ([@B36]); however, our study included a small number of patients (6 cases) with empyema without pulmonary parenchymal shadow, so the application of another severity score might be more appropriate.

In conclusion, the characteristics of *Klebsiella* chest infections as investigated by comparing them with pneumococcal chest infection included an old age, male predominance, impaired premorbid PS, an alcohol habit, some underlying diseases, a high frequency of developing lung abscess/necrotizing pneumonia and empyema, and a long duration of antibiotics administration and hospital stay. Severe cases of infection were also found in patients with *Klebsiella* spp. other than *K. pneumoniae*.
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